Aripiprazole (Abilify) and CYP2D6 Pharmacogenomics

What Is Aripiprazole?

Aripiprazole (brand name Abilify) is an atypical antipsychotic medication prescribed for schizophrenia, bipolar I disorder (acute manic and mixed episodes), adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and Tourette's disorder. It is one of the most widely prescribed atypical antipsychotics in the United States.

What makes aripiprazole relevant to pharmacogenomics is that it is primarily metabolized by the CYP2D6 enzyme, with a secondary contribution from CYP3A4. CYP2D6 poor metabolizers have approximately 80% higher aripiprazole exposure compared to normal metabolizers at the same dose, which the FDA labeling and CPIC guidelines address with specific dose adjustment recommendations.

How CYP2D6 Affects Aripiprazole Metabolism

After oral administration, aripiprazole is metabolized primarily by CYP2D6 and CYP3A4 to its active metabolite, dehydro-aripiprazole. CYP2D6 is the dominant pathway, and your CYP2D6 metabolizer status directly affects the balance between parent drug and metabolite.

In CYP2D6 poor metabolizers, the reduced clearance through CYP2D6 leads to higher plasma concentrations of aripiprazole. The active metabolite dehydro-aripiprazole has similar pharmacological activity, so the total active moiety (aripiprazole plus dehydro-aripiprazole) is elevated in poor metabolizers.

Because CYP3A4 provides a secondary pathway, CYP3A4 inhibitors (e.g., ketoconazole) can further increase aripiprazole levels, especially in CYP2D6 poor metabolizers where both pathways are compromised. Learn more about how pharmacogenomic testing works from raw DNA data.

Impact of CYP2D6 Metabolizer Status

Your CYP2D6 phenotype affects aripiprazole exposure at standard doses:

• Ultrarapid Metabolizer (UM): Increased CYP2D6 activity may result in lower aripiprazole levels. Limited data exists for specific dose recommendations. Standard dosing may result in subtherapeutic levels in some patients. Monitor for effectiveness.
• Normal Metabolizer (NM): Standard CYP2D6 function. Aripiprazole is metabolized at the expected rate. Standard dosing applies per prescribing information.
• Intermediate Metabolizer (IM): Moderately reduced CYP2D6 activity. Aripiprazole levels may be somewhat elevated. Standard starting dose may be appropriate, but monitoring for side effects is advisable.
• Poor Metabolizer (PM): Significantly reduced or absent CYP2D6 activity. Aripiprazole exposure is approximately 80% higher than in normal metabolizers. FDA labeling and CPIC guidelines recommend reducing the dose to approximately 50% of the standard dose.

For a plain-language explanation of metabolizer categories, read our guide to metabolizer status.

CPIC Guideline Summary

The aripiprazole–CYP2D6 interaction has a CPIC Level A classification — the strongest evidence level. FDA labeling includes CYP2D6-specific dosing recommendations, and CPIC guidelines align with these:

• NM: Initiate therapy at standard dose per prescribing information.
• IM: Standard starting dose may be appropriate. Monitor for adverse effects.
• PM: Reduce dose to approximately 50% of the standard dose. All dose adjustments should be directed by the prescriber based on the full clinical picture.
• UM: Insufficient data for specific dose increases. Standard dosing may result in lower drug levels. Monitor effectiveness and adjust under prescriber supervision.

Note that concurrent use of strong CYP3A4 inhibitors or inducers also requires dose adjustments regardless of CYP2D6 status. Your prescriber considers both genetic and drug interaction factors together.

Understanding Your Results

If you have raw DNA data from 23andMe, AncestryDNA, or another consumer service, DecodeMyBio can analyze your CYP2D6 status and report whether aripiprazole is flagged for your genotype. Your Psychiatric Medication Report will include your CYP2D6 diplotype, activity score, metabolizer phenotype, and the CPIC recommendation for aripiprazole specifically.

Aripiprazole response depends on many factors beyond CYP2D6 status, including other medications (especially CYP3A4 inhibitors or inducers), liver function, age, and clinical indication. See our methodology for how results are derived and our limitations page for important caveats.

Related Resources

• CYP2D6 and Psychiatric Medications
• Fluoxetine (Prozac) and CYP2D6
• Venlafaxine (Effexor) and CYP2D6
• Pharmacogenomic Testing for Depression
• Pharmacogenomics for Anxiety
• Compare Pharmacogenomics Testing Options
• Pharmacogenomics From Raw DNA Data

Frequently Asked Questions